Azenta Inc
NASDAQ:AZTA
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Azenta Inc
NASDAQ:AZTA
|
1.3B USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
195.3B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
147.9B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
79.2T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.7B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280.9B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.3B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.9B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.8B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.2B HKD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Azenta Inc
Glance View
Azenta Inc. emerged as a focused entity after the strategic divestiture of Brooks Automation's semiconductor business, carving out a niche to serve the life sciences industry with precision. The company's evolution is a testament to its strategic agility, aligning itself with the burgeoning demand for data-driven decision-making in healthcare and biotechnology. Azenta specializes in providing comprehensive solutions that revolve around sample management, genomic services, and automated storage systems. By ensuring the integrity and accessibility of biological samples and data, Azenta plays a crucial role in accelerating research and development processes. Its core operations are built upon intricate platforms that manage critical laboratory activities and genomic sequencing, enabling laboratories and research institutions to streamline their workflows and enhance productivity. Central to Azenta's business model is its recurring revenue stream derived from life science products and services, which supports labs in safeguarding and optimizing essential research materials. The company's offerings encompass robust automated systems, state-of-the-art genomic services, and logistics that ensure seamless sample management from collection to analysis. Through strategic partnerships and continuous innovation, Azenta effectively supports its clients in navigating the complexities of modern research, ultimately helping translate scientific endeavors into tangible outcomes. By continually expanding its technological capabilities and service offerings, Azenta not only fortifies its market position but also underscores its commitment to facilitating transformative advancements in life science and healthcare industries.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Azenta Inc is 44.6%, which is above its 3-year median of 42.3%.
Over the last 3 years, Azenta Inc’s Gross Margin has increased from 44.2% to 44.6%. During this period, it reached a low of 39.1% on Dec 31, 2023 and a high of 45.5% on Aug 30, 2025.